Results 81 to 90 of about 5,351 (123)

New Antibiotics for Lower Respiratory Tract Infections

Microbiology Research
Respiratory tract infections are frequently encountered in clinical practice. The growing incidence of antimicrobial resistance among the causative pathogens exerts sustained pressure on the existing therapeutic options.
Despoina Papageorgiou, Maria Gavatha, Dimitrios Efthymiou, Eleni Polyzou, Aristotelis Tsiakalos, Karolina Akinosoglou   +5 more
doaj   +1 more source

Systematic and quantitative analyses of hollow fiber model of Mycobacterium abscessus lung disease studies and new dosing recommendations

Microbiology Spectrum
Guideline-based combination therapy achieves sputum culture conversion rates in 23%–34% of patients with Mycobacterium abscessus-complex lung disease. Thus, new therapies are needed.
Shashikant Srivastava, Tawanda Gumbo
doaj   +1 more source

P-1215. In vitro activity of Sulbactam-durlobactam and Standard-of-Care Antibiotics against Acinetobacter baumannii-calcoaceticus complex isolates from wound and urinary tract sources: ACNBio Study 2023-2025 [PDF]

Open Forum Infect Dis
Background Acinetobacter baumannii most often causes nosocomial bacteremia and pneumonia. However, A. baumannii is becoming an important cause of a broader range of infections including skin and soft tissue infection (SSTI) and urinary tract infections ...
Kirn, Thomas, Chavez, Violeta, Westblade, Lars, Mutnal, Manohar B, Potula, Raghava, Daniels, Anne R, Pierce, Virginia M, Beck, Eric T, Narayanan, Navaneeth, Simner, Patricia J, Cyr, Elizabeth, Fisher, Mark, Argotsinger, Jill, Dumm, Rebekah, Gialanella, Philip, Kufel, Wesley D, Chamberland, Robin R, Marino, Jamie, Huse, Holly, Abbo, Lilian M, Hamilton-Seth, Robert, Riddell, Scott W, Jenkins, Timothy C, Harrington, Amanda, Asempa, Tomefa E, Hankins, Julia, Tibbetts, Robert, Vu, Christine A, Tekle, Tsigereda, Humphries, Romney, Clark, Andrew E, Mochon, Brian, Nicolau, David P, Martinez, Octavio, Hand, Jonathan, Liesman, Rachel   +35 more
europepmc   +2 more sources

The Role of Combination Antibiotic Therapy in Combatting Drug-Resistant Acinetobacter baumannii Infections: A Systematic Review of Randomised Control Trials

Antibiotics
Background: Acinetobacter baumannii is a major global health threat due to its rapid acquisition of multidrug resistance, particularly to carbapenems.
Anteneh Assefa Gezmu, Abel Workalemahu Tesfaye, Anthony R. M. Coates   +2 more
doaj   +1 more source

Evolution of an extensively antibiotic resistant sublineage of lineage 1 of GC1 Acinetobacter baumannii

npj Antimicrobials and Resistance
The multiply antibiotic-resistant lineage 1 of Acinetobacter baumannii global clone 1 (GC1) emerged in the 1970s, and subsequently more extensively resistant sublineages have emerged.
Christopher J. Harmer, Ting L. Luo, Francois Lebreton, Patrick T. McGann, Ruth M. Hall   +4 more
doaj   +1 more source

Zosurabalpin and the Revival of Pathogen-Specific Antibiotics: Targeting Lipopolysaccharide Transport in Carbapenem-Resistant Acinetobacter baumannii

Drugs and Drug Candidates
Carbapenem-resistant Acinetobacter baumannii (CRAB) is classified by the World Health Organization among the critical-priority pathogens, reflecting high mortality, near-ubiquitous nosocomial spread, and a depleted therapeutic pipeline.
Andrea Marino, Stefano Stracquadanio
doaj   +1 more source

What do We Know so Far about Ges Carbapenemases, and What Threat do They Pose?

Postępy Mikrobiologii
Carbapenemases, classified as bacterial enzymes, have the ability to hydrolyze carbapenems – important broad-spectrum antibiotics. This work attempts to summarize the information on the diversity of Guiana Extended-Spectrum (GES) subgroup of ...
Rutkowski Kamil, Osnytskyy Anton, Ślifierska Magdalena, Jarząbek Paulina, Bielec Filip, Pastuszak-Lewandoska Dorota, Brauncajs Małgorzata   +6 more
doaj   +1 more source

β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development

Pathogens
Antimicrobial resistance remains a public health problem of global concern with a great health and financial burden. Its recognition as a threat by political leadership has boosted the research and development of new antibiotics and particularly novel ...
Angeliki Katsarou, Panagiotis Stathopoulos, Iva D. Tzvetanova, Christina-Maria Asimotou, Matthew E. Falagas   +4 more
doaj   +1 more source

A Clinical Case of Treatment-Emergent Acinetobacter baumannii Non-Susceptibility to Sulbactam-Durlobactam. [PDF]

Clin Infect Dis
Sharara SL, Diaz L, Asempa TE, Martinez JRW, Canales N, Bergman Y, Murphy SG, Karaba SM, Clark AE, Zurawski DV, Cosgrove SE, Simner PJ, Munita JM, Tamma PD.   +13 more
europepmc   +1 more source

In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals

The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S ...
Cober, Eric, Hill, Carol, van Duin, David, Herc, Erica S, Bonomo, Robert A, Greenwood-Quaintance, Kerryl E, Chambers, Henry F, Arias, Cesar A, Fowler, Erin L, Baum, Keri, Doi, Yohei, Fowler, Vance G, Patel, Robin, McElheny, Christi L, Iovleva, Alina   +14 more
core   +1 more source